-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $50

Benzinga·02/02/2026 14:23:40
Listen to the news
Guggenheim analyst Yatin Suneja initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $50.